3 news items
Arcturus Therapeutics Announces First Quarter 2024 Financial Update and Pipeline Progress
ARCT
8 May 24
from license fees, consulting and related technology transfer fees, reservation fees and collaborative payments received from research and development
The Analyst Verdict: Arcturus Therapeutics In The Eyes Of 4 Experts
ARCT
11 Mar 24
medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in the segment of research
Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline Progress
ARCT
7 Mar 24
and related technology transfer fees, reservation fees and collaborative payments received from research and development arrangements with pharmaceutical
- Prev
- 1
- Next